Answers are grounded in this paper and cite their sources.
Shows dd-cfDNA predicts renal rejection in a UK kidney transplant cohort, suggesting fewer unnecessary biopsies.
Prior studies have shown that donor-derived cell-free DNA (dd-cfDNA) predicts renal biopsy-defined transplant rejection with a high negative predictive value (NPV). However, these studies were not in UK-based cohorts. The KORAD study aimed to assess relationships between dd-cfDNA levels and biopsy-defined rejection in a UK kidney transplant cohort, along with relationships with DSA and creatinine levels. dd-cfDNA was determined using AlloSeq cfDNA (CareDx) and DSA was identified with LABScreen single-antigen beads (Thermo Fisher Scientific). Eighty samples from 78 transplant patients had concomitant dd-cfDNA, DSA and creatinine results. The median percentage of dd-cfDNA in plasma samples with concomitant DSA negative results was significantly less than in DSA positive samples (0.37% vs. 3.15%, p = 0.002). There was no significant difference in the median percentage of dd-cfDNA in plasma samples with concomitant samples with elevated creatinine levels (0.41% vs. 0.36%, p = 0.779). Thirty-nine of these plasma samples had concomitant renal biopsy results. Thirty-two biopsies were negative for rejection and seven were positive for rejection. A receiver operating characteristic curve analysis showed that dd-cfDNA levels distinguished biopsy-defined rejection from no rejection with an acceptable AUC of 0.737 (95% CI, 0.485-0.987). The %dd-cfDNA threshold maximising overall correct classification was 0.7%. Using this threshold might have prevented 26 patients from undergoing renal biopsy unnecessarily, with two patients directed not to have a biopsy incorrectly (26 dd-cfDNA values being true negatives and two false negatives; NPV: 93% (95% CI, 83%-100%)), which outperformed the NPV for DSA: 88% (95% CI, 77%-99%) and creatinine 85% (95% CI, 69%-100%). We showed that the optimal dd-cfDNA threshold (0.7%) in this study was lower than the 1% threshold identified in non-UK studies. AlloSeq cfDNA (CareDx) with the optimal threshold showed an acceptable level of discrimination of biopsy-proven rejection and a potential to reduce the number of biopsies performed.
No takes yet. Share an insight, caveat, or question.
Flynn et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: